2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1587

A Phase 2a, 4-Week Double-Blind, Proof-of-Concept Efficacy and Safety Study of CC-292 Versus Placebo As Co-Therapy with Methotrexate in Active Rheumatoid Arthritis (RA)
Abstract Number: 1588

Treatment with BI 655064 (Antagonistic Anti-CD40 Antibody) Modulates Clinical and Biomarker Parameters Associated with Rheumatoid Arthritis (RA)
Abstract Number: 1589

Body Mass Index Does Not Impact Abatacept Retention in Biologic-Naive Patients with Rheumatoid Arthritis Who Have Poor Prognostic Factors: A 12-Month Interim Analysis of an Observational, Prospective Study
Abstract Number: 1590

Safety and Efficacy of Baricitinib in Elderly Patients with Moderate to Severe Rheumatoid Arthritis
Abstract Number: 1591

Efficacy and Safety of Switching from Adalimumab to Baricitinib: Phase 3 Data in Patients with Rheumatoid Arthritis
Abstract Number: 1592

A Randomized, Double-Blind, Parallel-Group, Phase III Study of Shortening the Dosing Interval of Subcutaneous Tocilizumab Monotherapy in RA Patients with an Inadequate Response to Subcutaneous Tocilizumab Every Other Week
Abstract Number: 1593

Baricitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Abstract Number: 1594

First-in-Human Pharmacokinetics and Safety of Escalating Single- and Multiple-Doses of GS-9876, a Novel, Oral SYK Inhibitor, in Healthy Subjects
Abstract Number: 1595

Magnitude and Duration of Early Response with Tofacitinib: Post-Hoc Analysis of Two Phase 3, Placebo-Controlled Studies
Abstract Number: 1596

Comparative Effectiveness of Tocilizumab Monotherapy with Tumor Necrosis Factor Inhibitors in Combination with Methotrexate in Patients with Rheumatoid Arthritis and Prior Exposure to Tumor Necrosis Factor Inhibitors
Abstract Number: 1597

Dose-Response Modeling Is a Useful Tool to Determine Doses for Phase 3: Experience from Olokizumab
Abstract Number: 1598

Olokizumab Treatment of Both Western and Asian Patients with Rheumatoid Arthritis Who Have Failed Anti-TNF Treatment Results in Sustained Improvements in Patient-Reported Outcomes
Abstract Number: 1599

Speed of Onset of Effect on Patient-Reported Outcomes Assessed through Daily Electronic Patient Diaries in the Baricitinib Phase 3 RA Clinical Program
Abstract Number: 1600

Evaluation of Disease Activity in Patients with Rheumatoid Arthritis Treated with Tofacitinib By RAPID3: An Analysis of Data from 6 Phase 3 Studies
Abstract Number: 1601

Maintenance Treatment Using Abatacept with Dose Reduction after Achievement of Low Disease Activity in Patients with Rheumatoid Arthritis (MATADOR) – a Prospective, Multicentered, Single Arm Clinical Trial

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].